Clinical lung cancer · 2024
The Potential of Basal F-18-FDG PET/CT in Evaluating Prognosis and Benefit From Adjuvant Chemotherapy After Tumor Resection of Stage IB(T2, ≤ 3 cm With VPI, N0, M0)NSCLC.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lei Bei, Zhang He, Sun Jianwen, Wang Lihua, Ruan Maomei, Yan Hui, Zhang Aimi, Chang Cheng, Yang Hao, Huang Gang, Liu Liu, Xie Wenhui
Аннотация
OBJECTIVES: To investigated whether the basal F-18-FDG PET/CT could evaluate the prognosis or the benefit from adjuvant chemotherapy after surgery of patients with early-stage NSCLC with visceral pleural invasion.
MATERIALS AND METHODS: A total of 116 patients with stage IB (T2, ≤ 3 cm with VPI, N0, M0) NSCLC underwent tumor resection and F-18-FDG PET/CT 1-3 weeks before surgery and were followed up for 1-79 months after surgery. SUVpeak, SUVmax, SUVmean, MTV, and TLG of tumors were obtained. The primary and secondary endpoints were progression-free survival (PFS) and overall survival (OS), respectively. ROC curve analysis, Cox regression test, and the Kaplan-Meier method were used for statistical analysis.
RESULTS: High SUVs, TLG, and MTV were associated with postoperative progression of NSCLC (the area under the ROC curve: 0.695 to 0.750, P < .001). The increase of SUVs, TLG or MTV was associated with short postoperative PFS (P < .001) while an increase in TLG (P = .016) or MTV (P = .018) was associated with short postoperative OS. TLG > 16.81 was an independent indicator of both the short PFS (HR = 5.534, P = .002) and the short OS (HR = 5.075, P = .031). Further, adjuvant chemotherapy was associated with longer PFS in NSCLCs with TLG > 16.81 (treated vs. untreated: 63 vs. 52 months; HR = 2.242, P = .022) rather than those with TLG ≤ 16.81.
CONCLUSION: SUV-based parameters on F-18-FDG PET/CT have the potential to evaluate the prognosis and benefit from adjuvant chemotherapy after tumor resection in stage IB (T2, ≤ 3 cm with VPI, N0, M0) NSCLC and therefore may be helpful for lung cancer treatment.
MATERIALS AND METHODS: A total of 116 patients with stage IB (T2, ≤ 3 cm with VPI, N0, M0) NSCLC underwent tumor resection and F-18-FDG PET/CT 1-3 weeks before surgery and were followed up for 1-79 months after surgery. SUVpeak, SUVmax, SUVmean, MTV, and TLG of tumors were obtained. The primary and secondary endpoints were progression-free survival (PFS) and overall survival (OS), respectively. ROC curve analysis, Cox regression test, and the Kaplan-Meier method were used for statistical analysis.
RESULTS: High SUVs, TLG, and MTV were associated with postoperative progression of NSCLC (the area under the ROC curve: 0.695 to 0.750, P < .001). The increase of SUVs, TLG or MTV was associated with short postoperative PFS (P < .001) while an increase in TLG (P = .016) or MTV (P = .018) was associated with short postoperative OS. TLG > 16.81 was an independent indicator of both the short PFS (HR = 5.534, P = .002) and the short OS (HR = 5.075, P = .031). Further, adjuvant chemotherapy was associated with longer PFS in NSCLCs with TLG > 16.81 (treated vs. untreated: 63 vs. 52 months; HR = 2.242, P = .022) rather than those with TLG ≤ 16.81.
CONCLUSION: SUV-based parameters on F-18-FDG PET/CT have the potential to evaluate the prognosis and benefit from adjuvant chemotherapy after tumor resection in stage IB (T2, ≤ 3 cm with VPI, N0, M0) NSCLC and therefore may be helpful for lung cancer treatment.